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doi:10.1016/j.jmii.2011.01.033Background: With the increasing experience of tigecycline usage, its ecological impact on
microorganisms raises concerns but remains unknown. We aimed to analyze the difference
in microorganisms isolated before, during, and after tigecycline usage and their susceptibility
to antimicrobial agents.
Methods: Between July 2008 and August 2009, 66 patients who received tigecycline monotherapy
formore than2 days at a Taiwanmedical centerwereenrolled. Antimicrobial susceptibility testing
was performed by brothmicrodilutionmethodwith VITEK-2 system andwas analyzed according to
theClinical and Laboratory Standards Institute guidelines, except for tigecycline.We followedUSA
Food and Drug Administration criteria for interpretation of susceptibility to tigecycline.
Results: The median duration of tigecycline monotherapy was 13.4 days. After tigecycline treat-
ment, the isolation frequency of Acinetobacter baumannii, methicillin-resistant Staphylococcus
aureus, Escherichia coli, and Klebsiella pneumoniae decreased, but that of Pseudomonas aerugi-
nosa, Proteus sp, and Stenotrophomonasmaltophiliadid not change.Abaumannii and P aerugino-
sa were the two most common pathogens when tigecycline was administered. The tigecycline
susceptibility rate of A baumannii isolates decreased after the administration of tigecycline.f Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital,
ou 1st Road, Kaohsiung City, Taiwan.
edu.tw (P.-L. Lu).
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Tigecycline exposure and microbial isolation 353Conclusion: The most common pathogens isolated in patients receiving tigecycline were A bau-
mannii and P aeruginosa. Tigecycline usage decreased the isolation frequency of A baumannii,
methicillin-resistant Saureus,Ecoli, andKpneumoniae. Exposureto tigecyclinemaybeassociated
with a decreased susceptibility rate of A baumannii for tigecycline.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Tigecycline, a 9-t-butylglycylamino derivative of minocy-
cline, is one of the latest glycylcycline antibiotics. It
overcomes two common tetracycline resistance mecha-
nisms mediated by acquired efflux pumps and ribosomal
protection.1 The characteristics of broad spectrum, rela-
tively low toxicity, and postantibiotic effect make tigecy-
cline an important antimicrobial agent in clinical practice.1
In 2009, the US Food and Drug Administration (FDA)
approved tigecycline for community-acquired pneumonia,
as well as for intraabdominal infection (IAI) and skin and
soft tissue infection.2 It is also effective in the treatment of
common multidrug-resistant gram-negative bacteria
encountered frequently in hospital-acquired infections,
including multidrug-resistant Acinetobacter baumannii,3
Stenotrophomonas maltophilia,4 and Clostridium diffi-
cile,5 although it is less effective against Pseudomonas
aeruginosa, Proteus sp, and Providencia sp.6
Use of many classes of antimicrobial agents has been
shown to be a risk factor for the colonization of or infection
by resistant pathogens. For example, extended spectrum b-
lactamase-producing Klebsiella pneumoniae and Escher-
ichia coli7 were shown to be associated with prior use of
fluoroquinolones and cephalosporins. A history of carba-
penem and fluroquinolone use was found to be associated
with carriage of carbapenem-resistant P aeruginosa.8 The
emergence of tigecycline resistance is associated with not
only tigecycline usage but also ciprofloxacin exposure.9 A
case report showed increased minimal inhibitory concen-
tration (MIC) of tigecycline during the treatment of carba-
penemase-producing K pneumoniae with tigecycline.10
Whether increasing level of tigecycline exposure plays
a role in the selection of tigecycline-resistant pathogens
still remains unknown. To investigate the ecological impact
of tigecycline on microbes and the antimicrobial suscepti-
bility of the organisms after tigecycline exposure, we
retrospectively analyzed bacterial isolates from patients
before, during, and after tigecycline exposure.
Materials and methods
The study was performed at a medical center in southern
Taiwan between July 2008 and August 2009 after receiving
approval from the hospital’s Institutional Review Board.
Patients were enrolled if they had received tigecycline
monotherapy for more than 48 hours. Patients who
received tigecycline as a part of a combination therapy
were excluded to avoid the influence of the coadminis-
trated antibiotics. Comorbidities were evaluated by Charl-
son Comorbidity score. The acute physiology and chronichealth evaluation II score of all the enrolled patients were
obtained at admission. Hospital-acquired infections were
defined at the date tigecycline was administered according
to the definition by Centers for Disease Control and
Prevention.11,12
Clinical isolates were categorized into three periods
depending on the time they were isolated: before-, during-,
and after-tigecycline periods. All available isolates in the
before-and during-tigecycline periods in the prehospital
and hospitalization course were included, whereas only
those collected within 2 weeks after tigecycline discontin-
uation were included in the after-tigecycline period. When
and which specimens to collect were decided by physicians
according to the clinical suspicion.
Blood culture was performed using Organon Teknika
BacT/Alert system, Massachusetts, United States. Urine
specimens were inoculated in sheep blood/eosin methylene
blue bi-plates. Respiratory secretions (sputum, endotra-
chial aspirate, and bronchial lavage) were inoculated in
colistin/nalidixic acid and chocolate agar. Species were
identified and antimicrobial susceptibility was tested by
VITEK-2 (bioMerieux, Inc., Saint Louis County, Missouri,
United States). The susceptibility testing results were
interpreted according to the Clinical and Laboratory Stan-
dards Institute guidelines, except for tigecycline.13 The USA
FDA criteria were followed for susceptibility interpretation
of tigecycline. The susceptibility interpretation criteria
were defined as susceptible for an MIC of tigecycline of
2 mg/mL, intermediate for an MIC of 4 mg/mL, and resis-
tant for an MIC of 8 mg/mL for gram-negative bacteria.14
Susceptibility testing of tigecycline for Gram-positive
bacteria was not regularly performed at our laboratory and
was performed by disk diffusion test upon clinician’s
request.
Statistical analysis
All data were analyzed by statistical package for social
sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA).
Changes in the frequencies of specific pathogens and their
susceptibilities were calculated for categorical variables by
using the Chi-squared test or Fisher’s exact test when 20%
of the expected count was less than five. A p value of less
than 0.05 was considered statistically significant (two-
tailed analysis).
Results
A total of 66 patients were included in this study. The
dosage of tigecycline for these patients was 100 mg loading
dose, followed by 50 mg every 12 hours, except for one
354 L.-Y. Chen et al.patient with liver cirrhosis who received half dose (25 mg
every 12 hours). Their demographic characteristics are lis-
ted in Table 1. The duration of tigecycline administration
ranged from 6 to 23 days (median, 13 days). Twenty-two
(33.3%) cases had hospital-acquired infections. Of the 66
patients, 31 (46%) were treated empirically, and 35 were
treated according to their microbiological culture results. A
baumannii (17/35, 48.5%) was the most common isolated
organisms.
Skin and soft tissue infection (22 patients, 33%) was the
most common infection site, followed by pulmonary
infection (20 patients, 30%) and IAI (17 patients, 25.7%).
Sixty-four (96%) patients survived for more than 2 weeks,
and 56(85%) patients survived during hospitalization. Five
patients died during tigecycline treatment and were
excluded from the data in the after-tigecycline period.
The antimicrobial agents used in the before-tigecycline
period are presented in Table 2. Before tigecycline
administration, most (41, 62%) of the patients received less
than 2 antibiotics, and 12 (18%) patients received more
than three antibiotics. Meropenem and piperacillin/tazo-
bactam were the most commonly used antibiotics before
tigecycline use.
Selection of microorganisms after tigecycline usage
Patient numbers of each common microorganism isolated in
the three separate periods are listed in Table 3. A bau-
mannii, P aeruginosa, and K pneumoniae were the three
most common pathogens during tigecycline treatment. Five
cases (7.5%) had isolation of bacterial strains other than
those causing their primary infections.Table 1 Demographics and characteristics of the 66 cases rece
Characteristics
Age (yr)
Comorbidity score
APACHE II score
Duration of tigecycline administration (d)
Average admission duration before tigecycline use (d)
Gender, n (%)
Male
Female
Source, n (%)
Community-acquired
Health care-related
Hospital-acquired
Underlying disease, n (%)
Liver cirrhosis
ESRD
CHF (grade 3, grade 4)
Diabetes mellitus
Malignancy
APACHEZ acute physiology and chronic health evaluation; CHF
SDZ standard deviation.P aeruginosa was isolated from 7 (10.6%) and 12 (18.18%)
patients before and after tigecycline use, respectively
(pZ 0.11, odds ratio [OR]: 0.53, 95% confidence interval
[CI]: 0.74e5.94). Between before and after tigecycline use,
A baumannii isolates decreased from 25% to 7% (p< 0.005,
OR: 0.26, 95% CI: 0.08e0.73). The frequency of methicillin-
resistant Staphylococcus aureus (MRSA) (p< 0.05, OR: 0.32,
95% CI: 0.098e1.09), E coli (p< 0.05, OR: 0.12, 95% CI:
0.01e0.52), and K pneumoniae (p< 0.05, OR: 0.28, 95% CI:
0.08e0.81) also decreased after tigecycline exposure.
Tigecycline had no significant impact on the isolation
frequency of Stenotrophomonas maltophilia (pZ 0.09, 95%
CI: 0.11e1.51), Proteus sp (pZ 0.23, 95% CI: 0.06e3.08),
Enterococcus sp (pZ 0.23, 95% CI: 0.04e1.68), and Candida
sp (pZ 0.09, 95% CI: 0.08e1.75) in after-tigecycline
period.
Changes in antibiotic susceptibility
At a median of 13 days after tigecycline treatment, the
tigecycline susceptibility rate decreased from 86% (before-
tigecycline) to 54% (after-tigecycline) in A baumannii
(pZ 0.04, OR: 0.2, 95% CI: 0.04e0.91) (Table 4). The
susceptibility to tigecycline for K pneumoniae and E coli
between before and after tigecycline usage was not
significantly different.
The susceptibility rates to antimicrobial agents for
Gram-negative isolates at each period are presented in
Table 5. Of the 22 strains of A baumannii, nine (40.9%)
remained susceptible to tigecycline but were isolated
during tigecycline treatment. Susceptibility rate was less
than 41% for all antimicrobial agents in the during-iving tigecycline
Mean SD
68.4 17.7
5.7 3.0
11.4 3.1
13.4 4.9
7.6 4.0
40 60.6
26 39.3
38 57.6
6 9.1
22 33.3
1 1.5
2 3.0
8 12.1
27 40.1
14 21.2
Z congestive heart failure; ESRDZ end stage renal disease;
Table 2 Antimicrobial treatment administered before tigecycline in 66 cases
Antimicrobial treatment Patient number
Piperacillin/tazobactam 36
Meropenem 28
Vancomycin 23
Ceftazidime 21
Fluconazole 11
Ampicillin/subactam 14
Ciprofloxacin 18
Levofloxacin 23
Teicoplanin 9
Eertapenem 7
Aamoxicillin/clavulanate 7
Cefpirome 5
Tigecycline exposure and microbial isolation 355tigecycline period. Susceptibility rate after discontinuation
of tigecycline was the highest for meropenem (46.2%)
compared with the other antibiotics. All Gram-positive
bacteria collected in the three periods remained suscep-
tible to vancomycin.
Discussion
Our study focuses on the ecological impact of tigecycline
exposure in real world practice and is different from the
study designs that focused on volunteer15 and association
studies on drug usage amount and resistance trends.16 We
found that the frequency of A baumannii, MRSA, E coli, and
K pneumoniae isolates decreased significantly after tige-
cycline usage. A previous study on healthy volunteers
revealed that, after 8 days of tigecycline exposure, the
stool colonization rates of E coli and Enterococcus sp
reduced, whereas the rate of yeasts increased.15 Our study
is different from other studies in the following respects: (1)
clinical infections but not fecal colonization were studied
and (2) effect of the antimicrobials other than tigecycline
that may have been prescribed before the initiation of
tigecycline treatment in clinical practice was not analyzedTable 3 Isolated microorganisms by patient number in the thre
Isolated microorganisms Before, n (%)
nZ 66
A baumanniia,b 17 (25.8)
P aeruginosa 7 (10.6)
E colia,b 14 (21.2)
K pneumoniaea,b 16 (24.2)
MRSAa,b 11 (16.7)
Enterococcus 6 (9.0)
S maltophiliab 9 (13.6)
Candida species 7 (10.6)
CoNS 5 (7.6)
Proteus species 4 (6.0)
Prevotella species 2 (3.0)
a Significantly decreased isolation frequency between “after-tigecy
b Significantly decreased isolation frequency between “during-tigec
CoNSZ Coagulase-negative Staphylococcus; MRSAZmethicillin-resistin this study. Beside the changes in common pathogens
isolated after tigecycline usage, A baumannii and P aeru-
ginosa were the two most common bacteria during the
tigecycline usage period.
The superinfection rate with tigecycline usage ranged
from 2.4% to 23.5% across different studies.17,18 Garcia-
Cabrera et al.17 had reported that P. aeruginosa caused
58.5% superinfections at an average of 8 days of tigecycline
treatment for nosocomial infections. Five cases (7.5%) in
the study had bacterial isolation other than those causing
their primary infections. However, there was no increase in
the isolation rate of P aeruginosa in our study, although it
ranked the first among the most frequent pathogens in
hospital-acquired infections and was responsible for 12.4%
(148/1186) of the cases reported in the study hospital in
2009 (Data from Infection Control Committee). Unlike in
a previous study,17 in this study, we included not only cases
of nosocomial infection. Besides, many cases in the study
received antipseudomonal antibiotics before tigecycline
treatment.
Candida infection has been considered a poor prognostic
factor in IAIs.19 Broad-spectrum antibiotics, such as carba-
penem20 and tigecycline,21 influence normal gut flora ande separate periods
During, n (%) After, n (%)
nZ 66 nZ 61
6 (9.0) 5 (8.2)
6 (9.0) 12 (19.7)
1 (1.5) 2 (3.3)
5 (7.6) 5 (8.2)
2 (3.0) 4 (6.6)
1 (1.5) 2 (3.3)
1 (1.5) 4 (6.6)
2 (3.0) 3 (4.9)
3 (4.5) 1 (1.6)
1 (1.5) 2 (3.3)
0 (0.0) 0 (0.0)
cline” and “before-tigecycline” groups
ycline” and “before-tigecycline” groups.
ant Staphylococcus aureus.
Table 4 Changes in isolate number and their tigecycline susceptibility of A baumannii, E coli, and K pneumoniae in the three
periods
A baumannii E coli K pneumoniae
Before
Isolate No. 35 15 20
Susceptibility (%) 86 100 95
During
Isolate No. 9 1 3
Susceptibility (%) 67 100 67
After
Isolate No. 11 2 5
Susceptibility (%) 54 50 60
Table 5 The antimicrobial susceptibility rates to Gram-negative pathogens in the three periods
Before, n (%) During, n (%) After, n (%)
Susceptibility 92 22 39
Tigecycline 65 (70.1) 9 (40.9) 13 (33.3)
Meropenem 52 (56.5) 9 (40.9) 18 (46.2)
Piperacillin/tazobactam 32 (34.8) 9 (40.9) 14 (35.9)
Ciprofloxacin 28 (30.4) 8 (36.4) 11 (28.2)
Levofloxacin 33 (35.9) 9 (40.9) 11 (28.2)
Ceftazidime 26 (28.2) 7 (31.8) 15 (38.5)
Cefpirome 28 (30.4) 7 (31.8) 15 (38.5)
356 L.-Y. Chen et al.have been known to increase Candida albicans colonization
in the gut in an animal study; however, this finding does not
indicate the occurrence of clinical Candida infection.22 The
impact of tigecycline on gut colonization was not assessed
in this study. Our results revealed that tigecycline did not
increase infections with clinical Candida species.
In the study, A baumannii was the most common path-
ogen for which tigecycline was prescribed. We found that
45% of the A baumannii isolated in the before-tigecycline
period were carbapenem-resistant. Tigecycline was repor-
ted to have similar MIC50 and MIC90 in both imipenem-
sensitive and imipenem-resistant Acinetobacter sp.22
Because 57% of A baumannii causing nosocomial infec-
tions in 13 Taiwan intensive care units were resistant to
carbapenem,23 tigecycline, colistin, or sulbactam is still
considered as an important treatment option. Although
tigecycline has not been approved for hospital-acquired
pneumonia, some studies report excellent tissue penetra-
tion in murine epithelial lung fluid of tigecycline24 and its
efficacy in Acinetobacter sp.3,22 Moreover, decreased
activity of tigecycline against A baumannii, as was found in
this study and was reported in a previous study,17 should be
considered for patients with persistent A baumannii infec-
tion because we noted A baumannii, secondary to P aeru-
ginosa, as one of the important superinfection pathogens
during tigecycline treatment. To avoid the selection of
tigecycline-resistant A baumannii, some authorities suggest
a higher mutant prevention concentration in the treatment
of carbapenem-resistant A baumannii.25 In view of the fact
that high dose of tigecycline usage has not been approved
by the US FDA, combination antimicrobial therapy has been
suggested to avoid tigecycline-resistant strains duringtreatment.26 Because no single antibiotic has a suscepti-
bility rate of more than 50% during- and after-tigecycline
treatment periods, combination therapy may be considered
in clinical practice when patients with infection symptoms
and signs are encountered during tigecycline therapy.
Our study has the following limitations. Microorganisms
isolated before-tigecycline and after-tigecycline periods
could have been affected by the administrated antimicro-
bials at both the periods. Besides, specimens were
collected on the basis of physician’s decision rather on the
basis of a regular culture procedure at fixed intervals.
In conclusion, we revealed that an average of 13.4 days
exposure of tigecycline was associated with a decreased
isolation frequency of A baumannii, MRSA, E coli, and
K pneumoniae. A baumannii and P aeruginosa should be
considered when clinicians choose empirical treatment for
patients failing to respond to tigecycline because they were
the most common pathogens in patients receiving tigecy-
cline. Decreased susceptibility of A baumannii for tigecy-
cline may occur in the process of tigecycline therapy.Acknowledgment
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